The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized COVID-19 patients with an inflammatory status. However, the effects of co-administering these medications aiming for more rapid patient recovery are controversial among practitioners. The potential benefits i...

Full description

Bibliographic Details
Main Authors: Farzaneh Dastan, Hamidreza Jamaati, Saghar Barati, Shahrzad Varmazyar, Sahar Yousefian, Elmira Niknami, Payam Tabarsi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
baricitinib, COVID-19
inflammation
pneumonia
SARS-CoV-2
tocilizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1265541/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1265541/full

Similar Items